Four countries, including France, have entered into an agreement with a pharmaceutical laboratory to ensure the EU’s supply of the vaccine against
Four countries, including France, have entered into an agreement with a pharmaceutical laboratory to ensure the EU’s supply of a vaccine against the virus.
This is a signature that carries great hope. An agreement has been reached between Germany, France, Italy and the Netherlands with the pharmaceutical company AstraZeneca to ensure the supply of the European Union with 300 million doses of a possible vaccine against the coronavirus, the German Ministry of Health announced on Saturday.
The pharmaceutical group created in 1999 by the merger of the Swedish Astra and the British Zeneca estimated in a statement that the number of doses could reach up to 400 million dollars. Express Train highlighted what is known about this potential future treatment.
Who can benefit?
If the four countries have signed the agreement, all members of the European Union who wish to do so will be able to participate in the vaccination program. The agreement actually foresees distribution to all member states that want to participate, depending on the size of their population,” the German ministry said.
Your support is essential. Subscribe for $1 support us
“We have separate supply chains for each continent [America / Europe]”, Pascal Soriot, CEO of AstraZeneca, adds his side on BFMTV.
ALSO READ >> Covid-19 vaccine: “making it mandatory would be a great gift for anti-vaccines”
“In order to ensure that the vaccines are available in large numbers very soon after the possible approval this year or next, the production capacity must be contractually guaranteed immediately,” the German health ministry claimed. “Quick action and a coordinated group of member states” will benefit “all EU citizens,” welcomed German Health Minister Jens Spahn.
“Access to the vaccine will be a key step in ensuring the protection of our citizens against the return of the pandemic,” his French counterpart replied, promising the first deliveries before the end of 2020.
When should the vaccine be available?
The development of this vaccine could be successfully completed by the end of the year, according to government sources in Germany. “We have done animal studies that have been positive and we have the results of the first phase of 1,000 volunteers in the United Kingdom which are encouraging. We will know if the vaccine works at the end of the third phase tests in the fall,” said Pascal Soriot on Sunday.
“We will have the results in the month of September, and we have already made several tens of millions of doses from the month of September/October and we will be able to deliver millions of doses from the month of October/November. […] With an increase at the end of the year and the beginning of next year,” he adds.
What is the price ?
According to the president of AstraZeneca France, Olivier Nataf, in an interview with franceinfo, “the vaccine will be distributed at cost price.” “It was the perspective and purpose of access to as many people as possible at the lowest price,” he says again.
ALSO READ >> Vaccine against Covid-19: what is known about the controversy surrounding the Sanofi group
According to him, the dose of the vaccine is “really not very expensive, about 2 euros per dose”. “The investment required to produce several billion doses. All the delivery we have agreed with different partners in the United States, the United Kingdom or even India, will allow us to develop up to 2 billion doses to the world,” he explains.
How does the vaccine work?
According to him, the vaccine can neutralize the virus by developing immunity in the patient. This vaccine is “a vaccine that is known to be based on a viral vector, he told franceinfo. It requires a virus that is inactivated, changes its genetic code to insert the genetic code that will allow you to produce the coronavirus protein. By producing this protein, the patient will be able develop an immune response against a characteristic protein of the coronavirus.”
READ ALSO >> Covid-19: researchers identify natural immunity, the way to a vaccine
“The reason why we are hopeful is that it is a technology developed by the University of Oxford, which has one of the best vaccinology groups in the world, and has already been tested against SARS and MERS,” adds Pascal Soriot, CEO.
other current trials?
About a hundred laboratories around the world are still involved in a race against time to develop a vaccine against the coronavirus, which has so far killed more than 417,000 people and infected more than 7.4 million people worldwide.
SEE ALSO >> VIDEO. Where is the race for a vaccine against the coronavirus?
In addition to AstraZeneca, other pharmaceutical companies have engaged with vocal encouragement. Ten of them have reached the stage of clinical trials. The American laboratory Moderna, for example, will introduce its experimental vaccine into the third and final phase of clinical trials in July on 30,000 volunteers, the company announced on Thursday. It is modern with the University of Oxford, which also launched a large test on 10,000 volunteers. However, its technology is based on messenger RNA, which has never been shown to be effective against other viruses.
At AstraZeneca, “if efficiency [of the vaccine] not proven, there could be different possible outcomes: either we can continue to have periods and have different results, or we can move on to something else. It’s not possible to put all your eggs in one basket and not have a candidate vaccine, so European governments will look for other deals, but ours seems to be one of the most advanced,” they hope. Olivier Nataf.
Read our full file
“COVID-19”, the new coronavirus
India, Iran, China… These countries are threatened by the second wave of the Sars coronavirus. Spain is in the lead until June 21st in the reopening of borders with EU countries. Scientists are trying to predict the evolution of the epidemic with their “models”.
Negotiations will continue with other pharmaceutical laboratories in order to maximize the possibility of rapid access to the vaccine in sufficient quantity and at the best price”, confirms Olivier Véran, French Minister of Health.
Date of update: June 14, 2020, 11:58 am
Categories: Optical Illusion
Source: newstars.edu.vn